Michael S. Khodadoust

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• A practical approach to risk stratification of incidental T cell clonality

  Blood Advances · 2026-06-18

• Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders

  The American Journal of Surgical Pathology · 2026-03-31

• 1168 Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-cell Lymphoproliferative Disorders

  Laboratory Investigation · 2026-03-01

• Abstract PS2-11-20: Recurrent ciliary alterations under neoadjuvant selection are associated with inferior breast cancer outcomes

  Clinical Cancer Research · 2026-02-17

• Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)

  medRxiv · 2026-02-04

• ‘Leukaemic pernio’: perniosis-like presentations of chronic lymphocytic leukaemia

  Clinical and Experimental Dermatology · 2026-01-22

• Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

  2025-12-11

• Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

  2025-12-11

• Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine

  Blood · 2025-11-25 · 6 citations

• Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

  Blood · 2025-11-03 · 1 citations

• Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

  Blood · 2025-11-03

• T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas

  Blood · 2025-11-03

• Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas

  Blood · 2025-11-03

• Pathologic and molecular characterization of CTCL with central nervous system or ocular involvement

  European Journal of Cancer · 2025-10-01

• JAK2 fusions in mycosis fungoides and Sézary Syndrome and treatment with ruxolitinib

  European Journal of Cancer · 2025-10-01

• A Phase 2 Study of Low-Dose Total Skin Electron Beam Therapy (LD-TSEBT) Combined with Mogamulizumab (TSE-Moga) in patients with Mycosis Fungoides (MF) and Sezary Syndrome (SS)

  European Journal of Cancer · 2025-10-01

• Abstract P1-02-19: Spatially defining T-cell clonal evolution in post-neoadjuvant breast cancer and association with molecular residual disease

  Clinical Cancer Research · 2025-06-13

• Abstract P4-03-17: Enhanced spatial detection of post-neoadjuvant breast cancer minimal residual disease by tissue-based Cancer Personalized Profiling by Deep Sequencing

  Clinical Cancer Research · 2025-06-13

• Abstract 6352: Defining spatial molecular residual disease by personalized tumor tissue profiling

  Cancer Research · 2025-04-21

• Abstract 3252: Circulating tumor DNA (ctDNA) enables enhanced measurable residual disease (MRD) detection and non-invasive clonal profiling in acute myeloid leukemia (AML)

  Cancer Research · 2025-04-21 · 1 citations